EP2678031A4 - Combined cell based gp96-ig-siv/hiv, recombinant gp120 protein vaccination for protection from siv/hiv - Google Patents

Combined cell based gp96-ig-siv/hiv, recombinant gp120 protein vaccination for protection from siv/hiv

Info

Publication number
EP2678031A4
EP2678031A4 EP12750264.9A EP12750264A EP2678031A4 EP 2678031 A4 EP2678031 A4 EP 2678031A4 EP 12750264 A EP12750264 A EP 12750264A EP 2678031 A4 EP2678031 A4 EP 2678031A4
Authority
EP
European Patent Office
Prior art keywords
siv
hiv
recombinant
protection
cell based
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP12750264.9A
Other languages
German (de)
French (fr)
Other versions
EP2678031A2 (en
Inventor
Eckhard R Podack
Natasa Strbo
Genoveffa Franchini
Monica Vaccari
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United States, AS REPRESENTED BY TH
University of Miami
Original Assignee
US Department of Health and Human Services
University of Miami
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services, University of Miami filed Critical US Department of Health and Human Services
Publication of EP2678031A2 publication Critical patent/EP2678031A2/en
Publication of EP2678031A4 publication Critical patent/EP2678031A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464476—Heat shock proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6043—Heat shock proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP12750264.9A 2011-02-23 2012-02-23 Combined cell based gp96-ig-siv/hiv, recombinant gp120 protein vaccination for protection from siv/hiv Withdrawn EP2678031A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161445884P 2011-02-23 2011-02-23
PCT/US2012/026256 WO2012116142A2 (en) 2011-02-23 2012-02-23 Combined cell based gp96-ig-siv/hiv, recombinant gp120 protein vaccination for protection from siv/hiv

Publications (2)

Publication Number Publication Date
EP2678031A2 EP2678031A2 (en) 2014-01-01
EP2678031A4 true EP2678031A4 (en) 2015-09-02

Family

ID=46721440

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12750264.9A Withdrawn EP2678031A4 (en) 2011-02-23 2012-02-23 Combined cell based gp96-ig-siv/hiv, recombinant gp120 protein vaccination for protection from siv/hiv

Country Status (9)

Country Link
US (1) US20140286991A1 (en)
EP (1) EP2678031A4 (en)
JP (1) JP2014508762A (en)
KR (1) KR20140045341A (en)
CN (1) CN103501807A (en)
AU (1) AU2012220592A1 (en)
CA (1) CA2828443A1 (en)
WO (1) WO2012116142A2 (en)
ZA (1) ZA201307069B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2717854C (en) 2008-03-03 2019-02-19 The University Of Miami Allogeneic cancer cell-based immunotherapy
EP2274001A4 (en) 2008-03-20 2012-08-01 Univ Miami Heat shock protein gp96 vaccination and methods of using same
WO2016007765A1 (en) 2014-07-11 2016-01-14 Gilead Sciences, Inc. Modulators of toll-like receptors for the treatment of hiv
SG11201705844SA (en) * 2015-02-06 2017-08-30 Heat Biologics Inc Vector co-expressing vaccine and costimulatory molecules
US11666649B2 (en) 2016-10-11 2023-06-06 University Of Miami Vectors and vaccine cells for immunity against Zika virus
WO2018187260A1 (en) 2017-04-04 2018-10-11 Heat Biologics, Inc. Intratumoral vaccination

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010060026A1 (en) * 2008-11-21 2010-05-27 University Of Miami Hiv/siv vaccines for the generation of mucosal and systemic immunity

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001257072A1 (en) * 2000-04-17 2001-10-30 Qais Al-Awqati Methods and compositions for heat shock protein mediated immunotherapy of melanoma
CZ20024154A3 (en) * 2000-06-26 2003-08-13 Stressgen Biotechnologies Corporation Use of a composition containing heat shock protein for treating warts, diseases, and states connected with papilloma virus
DK1363938T3 (en) * 2000-08-03 2014-03-24 Univ Johns Hopkins Molecular vaccine that connects an endoplasmic reticulum-chaperonepolypeptid with an antigen
GB0118367D0 (en) * 2001-07-27 2001-09-19 Glaxosmithkline Biolog Sa Novel use
EP1479689A1 (en) * 2003-05-21 2004-11-24 Biotech Tools S.A. Peptide complex
CN101351223A (en) * 2005-10-17 2009-01-21 诺华有限公司 Multiclade HIV vaccines
CN101057975B (en) * 2006-12-13 2012-10-10 中国科学院微生物研究所 Cocktail vaccine for anti immune tolerance and immunodeficiency virus and its application
CN101002949A (en) * 2006-12-25 2007-07-25 叶新新 HIV-Env gene DNA allosterism recombination envelope protein antigen for immunoresponsiveness of anti-HIV test and method

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010060026A1 (en) * 2008-11-21 2010-05-27 University Of Miami Hiv/siv vaccines for the generation of mucosal and systemic immunity

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BELSHE R B ET AL: "NEUTRALIZING ANTIBODIES TO HIV-1 IN SERONEGATIVE VOLUNTEERS IMMUNIZED WITH RECOMBINANT GP120 FROM THE MN STRAIN OF HIV-1", JAMA THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, AMERICAN MEDICAL ASSOCIATION, US, vol. 272, no. 6, 10 August 1994 (1994-08-10), pages 475 - 480, XP000197424, ISSN: 0098-7484, DOI: 10.1001/JAMA.272.6.475 *
DORIA-ROSE N A ET AL: "Human Immunodeficiency Virus Type 1 subtype B Ancestral Envelope Protein Is Functional and Elicits Neutralizing Antibodies in Rabbits Similar to Those Elicited by a Circulating Subtype B Envelope", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 79, no. 17, 1 September 2005 (2005-09-01), pages 11214 - 11224, XP008112620, ISSN: 0022-538X, DOI: 10.1128/JVI.79.17.11214-11224.2005 *
GEOFFREY J. GORSE ET AL: "HIV-1MN Recombinant Glycoprotein 160 Vaccine-Induced Cellular and Humoral Immunity Boosted by HIV-1MN Recombinant Glycoprotein 120 Vaccine", AIDS RESEARCH AND HUMAN RETROVIRUSES, vol. 15, no. 2, 20 January 1999 (1999-01-20), pages 115 - 132, XP055204334, ISSN: 0889-2229, DOI: 10.1089/088922299311547 *
MCFARLAND E J ET AL: "Human immunodeficiency virus type 1 (HIV-1) gp120-specific antibodies in neonates receiving an HIV-1 recombinant gp120 vaccine", JOURNAL OF INFECTIOUS DISEASES. JID, UNIVERSITY OF CHICAGO PRESS, CHICAGO, IL, vol. 184, no. 10, 15 November 2001 (2001-11-15), pages 1331 - 1335, XP002391888, ISSN: 0022-1899, DOI: 10.1086/323994 *
NATASA STRBO ET AL: "Gp96Ig immunization induces potent polyepitope specific, multifunctional memory responses in rectal and vaginal mucosa", VACCINE, ELSEVIER LTD, GB, vol. 29, no. 14, 17 January 2011 (2011-01-17), pages 2619 - 2625, XP028172311, ISSN: 0264-410X, [retrieved on 20110120], DOI: 10.1016/J.VACCINE.2011.01.044 *

Also Published As

Publication number Publication date
WO2012116142A3 (en) 2012-10-26
JP2014508762A (en) 2014-04-10
KR20140045341A (en) 2014-04-16
CA2828443A1 (en) 2012-08-30
CN103501807A (en) 2014-01-08
EP2678031A2 (en) 2014-01-01
AU2012220592A1 (en) 2013-09-12
WO2012116142A2 (en) 2012-08-30
ZA201307069B (en) 2016-01-27
US20140286991A1 (en) 2014-09-25

Similar Documents

Publication Publication Date Title
WO2013085550A3 (en) V1v2 immunogens
AU2016202543A1 (en) Human immunodeficiency virus (hiv)-neutralizing antibodies
EP2638072A4 (en) Fusion proteins for hiv therapy
SI3556396T1 (en) Human immunodeficiency virus (hiv)-neutralizing antibodies
EP2542703A4 (en) Novel hiv-1 envelope glycoprotein
EP2739300A4 (en) N-terminal deleted gp120 immunogens
SG10201508700XA (en) Recombinant subunit dengue virus vaccine
SG11201400432VA (en) Polypeptide vaccine
HK1204632A1 (en) Immunogens for hiv vaccination hiv
ZA201307069B (en) Combined cell based gp96-ig-siv/hiv, recombinant gp120 protein vaccination for protection from siv/hiv
HK1200329A1 (en) Truncated hiv envelope proteins (env), methods and compositions related thereto hiv (env)
IL222228A0 (en) Hiv vaccine
HK1207871A1 (en) Peptides derived from viral proteins for use as immunogens and dosage reactants
AU2011347268A8 (en) Recombinant Mycobacterium as a vaccine
HK1200870A1 (en) Use of non-subtype b gag proteins for lentiviral packaging b gag
WO2013052095A3 (en) Vaccine
WO2013190509A3 (en) Preparation of intermediates of boceprevir
EP2635300A4 (en) Dock-and-lock (dnl) constructs for human immunodeficiency virus (hiv) therapy
IL231494A0 (en) Chimeric non-intergating lentiviral genomes as vaccines against hiv-1
PT2643460T (en) Methods, compositions, and kits for determining human immunodeficiency virus (hiv)
EP2694654A4 (en) Protease cleavage site peptides as an hiv vaccine
EP3068427A4 (en) Hiv-1 env dna vaccine plus protein boost
GB201115136D0 (en) Bipolar electrode for fuel cell stacks
博闻 Autumn Leaves Are Fallng
IL236228A0 (en) Peptides derived from hiv gp41 for treating t-cell mediated pathologies

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20130821

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1193344

Country of ref document: HK

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: UNIVERSITY OF MIAMI

Owner name: THE UNITED STATES OF AMERICA, REPRESENTED BY THE S

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: THE UNITED STATES OF AMERICA, AS REPRESENTED BY TH

Owner name: UNIVERSITY OF MIAMI

A4 Supplementary search report drawn up and despatched

Effective date: 20150804

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/00 20060101AFI20150729BHEP

Ipc: A61K 39/21 20060101ALI20150729BHEP

Ipc: A61K 39/12 20060101ALI20150729BHEP

Ipc: A61K 35/17 20150101ALI20150729BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20160301

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1193344

Country of ref document: HK